PLK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1288427	0.59	20/20
SCHEMBL1288435	0.59	20/20
SCHEMBL1288431	0.56	20/20
SCHEMBL1288457	0.55	20/20
SCHEMBL1288333	0.54	20/20
SCHEMBL1288340	0.54	20/20
SCHEMBL1288372	0.54	20/20
SCHEMBL1288378	0.54	20/20
SCHEMBL1288306	0.72	19/20
SCHEMBL1288498	0.59	19/20
SCHEMBL1288503	0.59	19/20
SCHEMBL1288357	0.59	19/20
SCHEMBL1288359	0.59	19/20
SCHEMBL1288506	0.58	19/20
SCHEMBL1288512	0.58	19/20
SCHEMBL1288356	0.56	19/20
SCHEMBL1288360	0.56	19/20
SCHEMBL1288507	0.54	19/20
SCHEMBL1288511	0.54	19/20
SCHEMBL1288460	0.53	19/20

Clinical trials — most relevant to PLK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor	PHASE2	ACTIVE_NOT_RECRUITING
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma	PHASE2	COMPLETED
Protein Tyrosine Kinases (PTK) in Multiple Myeloma	PHASE2	COMPLETED
Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer	PHASE2	COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia	PHASE1	WITHDRAWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	PHASE1	COMPLETED
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer	PHASE1	COMPLETED
Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Implementing Patients´ Competence in Oral Breast Cancer Therapy	nan	UNKNOWN
Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PLK2 binder may also engage these)

Protein	Name	Similarity
Q5R4L1	—	1.000	Q5R4L1 →
Q9R012	—	1.000	Q9R012 →
P53351	—	1.000	P53351 →
P62205	—	1.000	P62205 →
P70032	—	0.993	P70032 →
Q91821	—	0.991	Q91821 →
Q9N2L7	—	0.990	Q9N2L7 →
MELK	Maternal embryonic leucine zipper kinase	0.989	landscape →
P52304	—	0.988	P52304 →
Q21029	—	0.987	Q21029 →
Q07832	—	0.987	Q07832 →
F1QGZ6	—	0.987	F1QGZ6 →
O54785	—	0.987	O54785 →
P32866	—	0.987	P32866 →
Q622Z7	—	0.986	Q622Z7 →
PTK2	Focal adhesion kinase 1	0.986	landscape →
Q2TA25	—	0.985	Q2TA25 →
Q69Z98	—	0.985	Q69Z98 →
MAP3K5	Mitogen-activated protein kinase kinase kinase 5	0.985	landscape →
Q62673	—	0.985	Q62673 →
Q07192	—	0.984	Q07192 →
P09560	—	0.984	P09560 →
Q28GW8	—	0.984	Q28GW8 →
O35099	—	0.984	O35099 →
P34152	—	0.984	P34152 →
Q61083	—	0.984	Q61083 →
Q09537	—	0.984	Q09537 →
Q2I6J1	—	0.984	Q2I6J1 →
Q62073	—	0.983	Q62073 →
PLK1	Serine/threonine-protein kinase PLK1	0.983	landscape →